Abbott Laboratories (ABT) Holder Timber Hill Boosted Position by $4.56 Million as Stock Value Rose; Serengeti Asset Management LP Has Upped Position in Irsa Inversiones Y Rep S A (IRS) by $2.18 Million as Valuation Declined

May 23, 2018 - By Ash

Abbott Laboratories (NYSE:ABT) Logo

Jody Lanasa increased its stake in Irsa Inversiones Y Rep S A (IRS) by 8.11% based on its latest 2017Q4 regulatory filing with the SEC. Serengeti Asset Management Lp bought 75,000 shares as the company’s stock declined 19.42% with the market. The hedge fund run by Jody Lanasa held 1.00 million shares of the homebuilding company at the end of 2017Q4, valued at $29.60M, up from 925,000 at the end of the previous reported quarter. Serengeti Asset Management Lp who had been investing in Irsa Inversiones Y Rep S A for a number of months, seems to be bullish on the $1.17 billion market cap company. The stock decreased 0.94% or $0.19 during the last trading session, reaching $20.11. About 62,381 shares traded. IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) has declined 2.74% since May 23, 2017 and is downtrending. It has underperformed by 14.29% the S&P500.

Timber Hill Llc increased its stake in Abbott Laboratories (ABT) by 730.9% based on its latest 2017Q4 regulatory filing with the SEC. Timber Hill Llc bought 79,968 shares as the company’s stock rose 5.88% while stock markets declined. The institutional investor held 90,909 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $5.19 million, up from 10,941 at the end of the previous reported quarter. Timber Hill Llc who had been investing in Abbott Laboratories for a number of months, seems to be bullish on the $107.63B market cap company. The stock decreased 1.16% or $0.72 during the last trading session, reaching $61.39. About 6.80 million shares traded or 7.90% up from the average. Abbott Laboratories (NYSE:ABT) has risen 34.85% since May 23, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Among 2 analysts covering IRSA Inversiones (NYSE:IRS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. IRSA Inversiones had 5 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Wednesday, November 23 by Morgan Stanley. On Thursday, February 8 the stock rating was downgraded by Morgan Stanley to “Hold”. Morgan Stanley downgraded IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) rating on Tuesday, August 11. Morgan Stanley has “Overweight” rating and $19 target. The stock has “Equal-Weight” rating by Morgan Stanley on Thursday, July 21. Zacks upgraded IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) on Monday, September 7 to “Hold” rating.

More news for IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) were recently published by: Seekingalpha.com, which released: “The Pips Are Squeaking” on May 16, 2018. Prnewswire.com‘s article titled: “IRSA Inversiones y Representaciones SA Announces Results for the third quarter of FY 2018 Ended March 31, 2018” and published on May 10, 2018 is yet another important article.

Serengeti Asset Management Lp, which manages about $2.16 billion and $511.19M US Long portfolio, decreased its stake in Altaba Inc by 10,000 shares to 50,000 shares, valued at $3.49 million in 2017Q4, according to the filing. It also reduced its holding in Pampa Energia S A (NYSE:PAM) by 190,000 shares in the quarter, leaving it with 125,000 shares, and cut its stake in Kkr & Co LP Del (Call) (NYSE:KKR).

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Streetinsider.com which released: “JPMorgan Remains Positive on Abbott (ABT), Expects Limited Impact from LVAD Recall” on May 22, 2018, also Streetinsider.com with their article: “Stifel Sees Minimal Impact from Abbott Labs (ABT) HeartMate III ‘Dear Doc Letter'” published on May 23, 2018, Streetinsider.com published: “Abbott (ABT) Reports 5-Yr FAME 2 Study Showing Positive Outcomes of Patients Using Diagnostic Tool” on May 22, 2018. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Seekingalpha.com and their article: “Abbott’s stent guide improved outcomes in long-term study” published on May 22, 2018 as well as Streetinsider.com‘s news article titled: “Abbott (ABT) Reports Positive Outcomes for First 100 Patients in Global Study of Investigational Tendyne Transcatheter …” with publication date: May 23, 2018.

Investors sentiment increased to 0.91 in 2017 Q4. Its up 0.04, from 0.87 in 2017Q3. It is positive, as 52 investors sold ABT shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. Mason Street Limited Company has 242,451 shares. Hardman Johnston Advisors Limited owns 49,558 shares. Sterling Cap Management Ltd Liability accumulated 2.11 million shares. Signature Financial Management holds 5,812 shares or 0.09% of its portfolio. Hartford Finance Management stated it has 1.34% of its portfolio in Abbott Laboratories (NYSE:ABT). Tiverton Asset Management Ltd has 0.69% invested in Abbott Laboratories (NYSE:ABT) for 193,104 shares. Auxier Asset Management holds 1.14% or 104,386 shares. Wallace Cap owns 4,135 shares for 0.04% of their portfolio. Moreover, Dekabank Deutsche Girozentrale has 0.29% invested in Abbott Laboratories (NYSE:ABT). Fayez Sarofim And has invested 1.2% of its portfolio in Abbott Laboratories (NYSE:ABT). California Pub Employees Retirement Systems holds 0.31% in Abbott Laboratories (NYSE:ABT) or 4.08M shares. Amica Pension Fund Board Of Trustees reported 93,592 shares. M&R Mgmt reported 0.31% in Abbott Laboratories (NYSE:ABT). Mogy Joel R Inv Counsel Incorporated holds 69,566 shares. First Comml Bank Tru holds 9,766 shares or 0.36% of its portfolio.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 107 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Tuesday, September 13. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Tuesday, June 21 by Edward Jones. The stock has “Buy” rating by Jefferies on Tuesday, March 15. The rating was maintained by Argus Research on Friday, July 21 with “Buy”. The rating was maintained by Stifel Nicolaus on Wednesday, January 24 with “Buy”. The firm has “Overweight” rating given on Wednesday, October 7 by Barclays Capital. The rating was maintained by BMO Capital Markets on Wednesday, January 24 with “Buy”. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) on Friday, October 9 with “Outperform” rating. On Friday, January 29 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock has “Buy” rating by BTIG Research on Saturday, August 29.

Since December 14, 2017, it had 1 buying transaction, and 21 sales for $23.88 million activity. 459 shares were sold by PEDERSON MICHAEL J, worth $27,213 on Friday, February 16. Bracken Sharon J sold $125,909 worth of stock or 2,150 shares. On Wednesday, January 31 Blaser Brian J sold $1.73M worth of Abbott Laboratories (NYSE:ABT) or 27,733 shares. The insider BIRD ROGER sold 8,262 shares worth $518,450. Ford Robert B also sold $2.69M worth of Abbott Laboratories (NYSE:ABT) on Tuesday, January 30. 3,000 shares were sold by Salvadori Daniel Gesua Sive, worth $183,592.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: